Los Angeles-based Cedars-Sinai has received more than $20 million to study potential treatments for heart failure and arrhythmogenic cardiomyopathy.
The funding comes from two separate grants — each more than $10 million — from the California Institute for Regenerative Medicine, according to a Dec. 11 news release from Cedars-Sinai.
One grant will support preclinical studies that combine RNA drug TY1 with semaglutide for the treatment of heart failure. The second grant will study a treatment for arrhythmogenic cardiomyopathy, the leading cause of sudden cardiac death in athletes and young people.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
